ClinicalTrials.gg
RecruitingNCT07121010Updated Oct 6, 2026

How Animal and Plant Protein Shakes Change the Body's Nutrient and Health Responses

An interventional study of Animal-Based Protein Smoothie and Plant-Based Protein Smoothie in Cardiometabolic Health, sponsored by University of Pittsburgh. Recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by University of Pittsburgh · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 6, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 468 studies in Atherosclerosis with a site in United States — 47 open to participants now, 75 under way, 17 of them phase 3. Atherosclerosis · United States.

Planned enrollment
283rd of 328
20 · median 119
Started
2026
with 13 others
No phase
103 of 468
21 open now
Primary completion
2026-12
later than 17 of 70 live
Registered
445th of 468
by date

Among the 468 studies in Atherosclerosis with a site in United States, this one is the 283rd largest by planned enrollment of the 328 interventional ones that give a count, is one of 14 that started in 2026, is one of 103 with no phase, reaches primary completion later than 17 of the 70 other live ones, and was the 445th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

47 of the 468 studies in Atherosclerosis with a site in United States are open now. Recruiting first, the newest first:

41 more — sign in →

All 47 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 468 studies in Atherosclerosis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn how different protein types affect the body's metabolism and immune system in healthy adults. The main questions it aims to answer are:

Does drinking smoothies with animal-based or plant-based protein change the level of amino acids like leucine in the blood?

Does adding leucine to a plant-based smoothie make the body respond like it does to an animal-based smoothie?

Participants will:

Come to the research clinic for 3 study visits

Drink a high-protein smoothie at each visit (one with animal protein, one with plant protein, and one with plant protein + leucine)

Give blood samples before and 1 and 3 hours after each smoothie

Researchers will look at how the body's metabolism and immune system respond. They are especially interested in a pathway called mTOR, which helps control how cells use nutrients and may be involved in heart disease like atherosclerosis.

All smoothies are prepared to meet Halal and Kosher dietary guidelines.

Read the detailed description

This is a randomized, controlled, crossover clinical trial designed to investigate the acute effects of dietary protein source and leucine supplementation on circulating amino acids and downstream metabolic and immune signaling pathways in healthy adults. The study is being conducted by researchers at the University of Pittsburgh and is based on emerging evidence that dietary protein composition-particularly the type and amount of amino acids such as leucine-may influence key biological processes associated with cardiometabolic health.

Proteins are an essential part of the human diet, and different protein sources (plant vs. animal) contain varying amounts and types of amino acids. One amino acid of particular interest is leucine, a branched-chain amino acid (BCAA) known to activate the mTOR (mechanistic target of rapamycin) signaling pathway. The mTOR pathway plays a critical role in regulating cell growth, metabolism, immune responses, and energy use. Excessive or chronic activation of this pathway has been implicated in cardiometabolic diseases, including atherosclerosis, obesity, insulin resistance, and inflammation.

Animal-derived proteins such as milk or meat tend to be richer in leucine than plant-derived proteins like soy or pea protein. This difference may explain some of the metabolic disparities observed between diets high in animal protein versus plant protein. While plant-based diets are often recommended for their anti-inflammatory and cardiovascular benefits, they may lack sufficient leucine to activate anabolic signaling pathways in certain tissues. It remains unclear whether supplementing plant-based protein with free leucine can achieve the same biological responses as animal protein ingestion.

The trial includes three study arms: (1) a smoothie containing only plant-based protein, (2) a smoothie containing animal-based protein, and (3) a plant-based smoothie with added free leucine. Each smoothie is isocaloric and matched in macronutrient content, differing only in protein source and leucine content. All meals will be prepared and administered under controlled conditions at the Clinical and Translational Research Center (CTRC) at UPMC Montefiore.

Participants will be healthy adults without chronic illnesses or recent infections, aged 18 years and older. Each participant will complete all three study visits in a randomized order, with a minimum 3-day washout period between visits. At each visit, participants will be asked to fast for 10 hours overnight before arriving at the CTRC in the morning. Upon arrival, fasting blood will be collected, followed by consumption of the assigned test smoothie. Additional blood samples will be collected at 1 and 3 hours post-consumption to evaluate postprandial responses.

Blood samples will be analyzed for:

Circulating amino acid levels (primary: leucine)

mTORC1 signaling activity in peripheral blood mononuclear cells (PBMCs), assessed via phosphorylation of S6 kinase (pS6)

Inflammatory and immune signaling markers (e.g., IL-6, NF-κB)

Exploratory transcriptomic profiling and broader amino acid analysis if resources allow

The main hypotheses are:

Animal-based protein will induce higher postprandial leucine levels and stronger mTORC1 activation than plant-based protein.

Supplementation of free leucine in the plant-based smoothie will mimic the biological effects of the animal protein smoothie on immune/metabolic responses.

The findings from this study could provide novel insights into how different dietary proteins modulate nutrient sensing and immune pathways. If plant-based protein supplemented with leucine proves to mimic the effects of animal protein, this could support more sustainable and heart-healthy dietary recommendations without compromising key metabolic functions.

Ultimately, this study will contribute to a deeper understanding of the nutritional regulation of mTOR and inflammation in humans and may inform future dietary interventions aimed at preventing or mitigating chronic cardiometabolic diseases such as atherosclerosis and diabetes.

03

Conditions studied

  • Cardiometabolic Health

Browse trials for

Keywords

  • mTOR Signaling
  • Dietary Protein
  • Cardiometabolic Disease
  • Atherosclerosis
  • Nutrient Signaling
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-65 years
  2. 18.5-29.9 kg/m²
  3. Generally healthy, without known chronic illness and/or treatment with chronic medications
  4. Willing to comply with dietary restrictions and study procedures
  5. Not currently following a prescribed or restrictive diet (for example, vegan, ketogenic or high-protein regimen) or regularly taking high-protein supplements

Exclusion criteria

Exclusion Criteria:

  1. History of cardiovascular disease, diabetes, or disorders
  2. Active use of anti-inflammatory, immunomodulatory, or lipid-lowering medications
  3. Renal or hepatic dysfunction
  4. Pregnancy or breastfeeding
  5. Allergies or intolerances to components of study meals. A list of the smoothie ingredients will be sent to the potential participant with the mailing of the consent form
  6. Participation in another interventional study within the last 30 days
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Animal → Plant → Plant+Leucine

    Participants in this arm will receive the animal-based protein smoothie during their first visit, the plant-based protein smoothie during their second visit, and the plant-based protein smoothie with added leucine during their third visit. All study visits follow the same protocol, including fasting, blood draws, and postprandial assessments.

    Dietary Supplement: Animal-Based Protein Smoothie · Dietary Supplement: Plant-Based Protein Smoothie · Dietary Supplement: Plant-Based Protein Smoothie with Leucine

  • Experimental
    Plant-Based → Plant-Based with Leucine → Animal-Based

    Participants in this arm will receive the plant-based protein smoothie first, the plant-based protein smoothie with leucine second, and the animal-based protein smoothie third. All clinical procedures are the same across visits.

    Dietary Supplement: Animal-Based Protein Smoothie · Dietary Supplement: Plant-Based Protein Smoothie · Dietary Supplement: Plant-Based Protein Smoothie with Leucine

  • Experimental
    Plant-Based with Leucine → Animal-Based → Plant-Based

    Participants in this arm will receive the plant-based protein smoothie with leucine at their first visit, the animal-based smoothie second, and the plant-based protein smoothie third. The same procedures will be followed at each visit.

    Dietary Supplement: Animal-Based Protein Smoothie · Dietary Supplement: Plant-Based Protein Smoothie · Dietary Supplement: Plant-Based Protein Smoothie with Leucine

Interventions

  • Dietary supplementAnimal-Based Protein Smoothie

    This smoothie is formulated to deliver 50% of its total caloric content from high-quality animal-based protein, such as whey protein isolate or pasteurized egg whites. It is designed to evaluate the postprandial metabolic and immune response to animal-derived protein sources. The smoothie does not contain any added free amino acids and is prepared in a food-safe certified kitchen under standardized conditions. All participants consume the smoothie after an overnight fast to ensure consistency in metabolic assessment.

  • Dietary supplementPlant-Based Protein Smoothie

    This smoothie is formulated to deliver 50% of its total caloric content from plant-based protein, such as pea or rice protein isolate. It is designed to evaluate the postprandial metabolic and immune response to plant-derived protein sources. The smoothie does not contain any added free amino acids and is prepared in a food-safe certified kitchen under standardized conditions. All participants consume the smoothie after an overnight fast to ensure consistency in metabolic assessment.

  • Dietary supplementPlant-Based Protein Smoothie with Leucine

    This smoothie is formulated to deliver 50% of its total caloric content from plant-based protein, using sources such as pea or rice protein isolate. In addition, it is supplemented with pharmaceutical-grade leucine to match the leucine content typically found in animal-based protein sources. The smoothie is designed to assess whether leucine supplementation can modulate the postprandial metabolic and immune response to plant-derived protein. It is prepared in a food-safe certified kitchen and consumed after an overnight fast to maintain consistency across study conditions.

06

What researchers measure

Primary outcomes

  1. Change in Circulating Serum Leucine Concentration

    This outcome measures the change in circulating serum leucine concentration from fasting baseline to 1 and 3 hours postprandially following ingestion of each of the three test meals: animal-based protein, plant-based protein, and plant-based protein supplemented with free leucine. Values will be compared within participants across the three meal conditions to assess how protein source and leucine content affect postprandial amino acid levels. Serum leucine will be quantified using targeted mass spectrometry. Unit of Measure: Micromoles per liter (μmol/L)

    Time frame: From enrollment to final blood draw at 4 weeks

Secondary outcomes

  1. Change in Monocyte mTORC1 Signaling Activity

    This outcome measures the change in mTORC1 signaling activity in peripheral blood mononuclear cells (PBMCs) from fasting to 1 and 3 hours after meal ingestion. mTORC1 activation will be quantified by assessing phosphorylation of S6 kinase (pS6K) using flow cytometry and/or Western blotting. Results will be compared within participants across the three dietary interventions-animal-based protein, plant-based protein, and plant-based protein supplemented with leucine-to determine the effect of protein source and leucine content on monocyte nutrient sensing. Unit of Measure: Relative band intensity (Western blot) or % pS6+ cells (flow cytometry)

    Time frame: From enrollment to final blood draw at 4 weeks

  2. Change in Serum IL-6 Concentration

    Serum IL-6 concentration will be measured using ELISA to evaluate the inflammatory response to different protein sources and leucine supplementation. Unit of Measure: pg/mL

    Time frame: From enrollment to final blood draw at 4 weeks

  3. Change in Serum TNF-α Concentration

    Serum TNF-α concentration will be measured using ELISA to evaluate the inflammatory response to different protein sources and leucine supplementation. Unit of Measure: pg/ml

    Time frame: From enrollment to final blood draw at 4 weeks

  4. Change in Serum C-Reactive Protein (CRP) Concentration

    Serum CRP concentration will be measured using ELISA to evaluate the inflammatory response to different protein sources and leucine supplementation. Unit of Measure: mg/L

    Time frame: From enrollment to final blood draw at 4 weeks

Other outcomes

  1. Exploratory Change in Additional Serum Amino Acid Concentrations

    If budget and sample quality allow, additional serum amino acids beyond leucine will be measured using targeted mass spectrometry to evaluate broader metabolic responses to dietary protein source and leucine supplementation. Unit of Measure: μmol/L

    Time frame: From enrollment to final blood draw at 4 weeks

  2. Exploratory Change in PBMC Gene Expression Profiles

    If resources permit, transcriptomic profiling of peripheral blood mononuclear cells (PBMCs) will be performed to assess dietary protein-induced changes in expression of metabolic and inflammatory gene pathways. Unit of Measure: log₂ fold change

    Time frame: From enrollment to final blood draw at 4 weeks

07

Study locations

1 of 1 sites recruiting
  • UPMC Montefiore - Clinical and Translational Research Center (CTRC)
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — There are no current plans to share individual participant data (IPD) or specimens outside the research team. All data collected during the study will be securely stored and maintained by the University of Pittsburgh research team in compliance with institutional data security standards. De-identified data or biospecimens may be used for future research within the institution or shared with collaborators only under appropriate data use or material transfer agreements and with required regulatory approvals.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Of 178 non-industry interventional studies with no phase under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's planned 9 months is below that.

Counting every sponsor, half of 198 studies reached it within 30 months; a quarter within 17 and three quarters within 56.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Sep 2026 → Dec 2026 and completion Oct 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2025
First posted
Aug 13, 2025
StartActual
Mar 24, 2026
Primary completionEst.
Dec 2026was Sep 2026
CompletionEst.
Mar 2027was Oct 2026
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Sep 2026→Dec 2026
Oct 6, 2026
Study completion
Oct 2026→Mar 2027
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Primary completion Sep 2026→Dec 2026
    Study completion Oct 2026→Mar 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07121010
Responsible party
Ali Ajam (Postdoctoral Associate, University of Pittsburgh) — Principal investigator
First posted
Aug 13, 2025
Start date
Mar 24, 2026
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Oct 6, 2026

Study contacts

Ali Ajam, MD
Contact
ala449@pitt.edu
412-512-1044
Babak Razani, MD-PhD
Contact
brazani@pitt.edu
412-648-7496
Babak Razani, MD-PhD
study director · University of Pittsburgh

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion